These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

452 related items for PubMed ID: 11346867

  • 21. The Pathologic Finding of Combined Lobular Carcinoma In Situ and Invasive Lobular Cancer May Indicate more than Just a High-Risk Marker Role of Lobular Carcinoma In Situ.
    Jean-Louis CJ, Masdon J, Smith B, Battles O, Dale P.
    Am Surg; 2017 May 01; 83(5):482-485. PubMed ID: 28541858
    [Abstract] [Full Text] [Related]

  • 22. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.
    Di Saverio S, Catena F, Santini D, Ansaloni L, Fogacci T, Mignani S, Leone A, Gazzotti F, Gagliardi S, De Cataldis A, Taffurelli M.
    Breast Cancer Res Treat; 2008 Jun 01; 109(3):405-16. PubMed ID: 17687650
    [Abstract] [Full Text] [Related]

  • 23. Local recurrence patterns in breast cancer patients treated with oncoplastic reduction mammaplasty and radiotherapy.
    Eaton BR, Losken A, Okwan-Duodu D, Schuster DM, Switchenko JM, Mister D, Godette K, Torres MA.
    Ann Surg Oncol; 2014 Jan 01; 21(1):93-9. PubMed ID: 24081796
    [Abstract] [Full Text] [Related]

  • 24. Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence.
    Shen J, Hunt KK, Mirza NQ, Buchholz TA, Babiera GV, Kuerer HM, Bedrosian I, Ross MI, Ames FC, Feig BW, Singletary SE, Cristofanilli M, Meric-Bernstam F.
    Cancer; 2005 Aug 01; 104(3):479-90. PubMed ID: 15968686
    [Abstract] [Full Text] [Related]

  • 25. Synchronous lobular carcinoma in situ and invasive lobular cancer: marker or precursor for invasive lobular carcinoma.
    Wallace AS, Xiang D, Hockman L, Arya M, Jeffress J, Wang Z, Dale PS.
    Eur J Surg Oncol; 2014 Oct 01; 40(10):1245-9. PubMed ID: 24857380
    [Abstract] [Full Text] [Related]

  • 26. Lobular carcinoma in situ: observation without surgery as an appropriate therapy.
    Carson W, Sanchez-Forgach E, Stomper P, Penetrante R, Tsangaris TN, Edge SB.
    Ann Surg Oncol; 1994 Mar 01; 1(2):141-6. PubMed ID: 7834439
    [Abstract] [Full Text] [Related]

  • 27. Presence of lobular carcinoma in situ does not increase local recurrence in patients treated with breast-conserving therapy.
    Ciocca RM, Li T, Freedman GM, Morrow M.
    Ann Surg Oncol; 2008 Aug 01; 15(8):2263-71. PubMed ID: 18506537
    [Abstract] [Full Text] [Related]

  • 28. Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases.
    Komoike Y, Akiyama F, Iino Y, Ikeda T, Akashi-Tanaka S, Ohsumi S, Kusama M, Sano M, Shin E, Suemasu K, Sonoo H, Taguchi T, Nishi T, Nishimura R, Haga S, Mise K, Kinoshita T, Murakami S, Yoshimoto M, Tsukuma H, Inaji H.
    Cancer; 2006 Jan 01; 106(1):35-41. PubMed ID: 16333848
    [Abstract] [Full Text] [Related]

  • 29. Improving local control with breast-conserving therapy: a 27-year single-institution experience.
    Cabioglu N, Hunt KK, Buchholz TA, Mirza N, Singletary SE, Kuerer HM, Babiera GV, Ames FC, Sahin AA, Meric-Bernstam F.
    Cancer; 2005 Jul 01; 104(1):20-9. PubMed ID: 15912514
    [Abstract] [Full Text] [Related]

  • 30. Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy.
    Rudloff U, Brogi E, Brockway JP, Goldberg JI, Cranor M, Wynveen CA, Nehhozina T, Reiner AS, Patil S, Van Zee KJ.
    Cancer; 2009 Mar 15; 115(6):1203-14. PubMed ID: 19170233
    [Abstract] [Full Text] [Related]

  • 31. Lobular carcinoma in situ and invasive cancer: the contralateral breast controversy.
    Carolin KA, Tekyi-Mensah S, Pass HA.
    Breast J; 2002 Mar 15; 8(5):263-8. PubMed ID: 12199752
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The impact of age on the risk of ipsilateral breast tumor recurrence after breast-conserving therapy in breast cancer patients with a > 5 mm margin treated without boost irradiation.
    Ono Y, Yoshimura M, Hirata K, Yamauchi C, Toi M, Suzuki E, Takada M, Hiraoka M, Mizowaki T.
    Radiat Oncol; 2019 Jul 10; 14(1):121. PubMed ID: 31291997
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Similar long-term results of breast-conservation treatment for Stage I and II invasive lobular carcinoma compared with invasive ductal carcinoma of the breast: The University of Pennsylvania experience.
    Santiago RJ, Harris EE, Qin L, Hwang WT, Solin LJ.
    Cancer; 2005 Jun 15; 103(12):2447-54. PubMed ID: 15887223
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Local recurrence after ductal carcinoma in situ breast conserving treatment. Analysis of 195 cases.
    Cutuli B, Lemanski C, Le Blanc-Onfroy M, de Lafontan B, Cohen-Solal-Le-Nir C, Fondrinier E, Mignotte H, Giard S, Charra-Brunaud C, Auvray H, Gonzague-Casabianca L, Quétin P, Fay R.
    Cancer Radiother; 2013 Jun 15; 17(3):196-201. PubMed ID: 23538041
    [Abstract] [Full Text] [Related]

  • 38. Impact of an In Situ Component on Outcome After In-Breast Tumor Recurrence in Patients Treated with Breast-Conserving Therapy.
    Laird J, Lok B, Siu C, Cahlon O, Khan AJ, McCormick B, Powell SN, Cody H, Wen HY, Ho A, Braunstein LZ.
    Ann Surg Oncol; 2018 Jan 15; 25(1):154-163. PubMed ID: 29094250
    [Abstract] [Full Text] [Related]

  • 39. Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study.
    Ottesen GL, Graversen HP, Blichert-Toft M, Christensen IJ, Andersen JA.
    Breast Cancer Res Treat; 2000 Aug 15; 62(3):197-210. PubMed ID: 11072784
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.